The DOI matches its Crossref record; 302 of the 302 references it cites were found in a registry or an index.
Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
Open accessAbstract
Tumor growth and metastasis rely on tumor vascular network for the adequate supply of oxygen and nutrients. Tumor angiogenesis relies on a highly complex program of growth factor signaling, endothelial cell (EC) proliferation, extracellular matrix (ECM) remodeling, and stromal cell interactions. Numerous pro-angiogenic drivers have been identified, the most important of which is the vascular endothelial growth factor (VEGF). The importance of pro-angiogenic inducers in tumor growth, invasion and extravasation make them an excellent therapeutic target in several types of cancers. Hence, the number of anti-angiogenic agents developed for cancer treatment has risen over the past decade, with at least eighty drugs being investigated in preclinical studies and phase I-III clinical trials. To date, the most common approaches to the inhibition of the VEGF axis include the blockade of VEGF receptors (VEGFRs) or ligands by neutralizing antibodies, as well as the inhibition of receptor tyrosine kinase (RTK) enzymes. Despite promising preclinical results, anti-angiogenic monotherapies led only to mild clinical benefits. The minimal benefits could be secondary to primary or acquired resistance, through the activation of alternative mechanisms that sustain tumor vascularization and growth. Mechanisms of resistance are categorized into VEGF-dependent alterations, non-VEGF pathways and stromal cell interactions. Thus, complementary approaches such as the combination of these inhibitors with agents targeting alternative mechanisms of blood vessel formation are urgently needed. This review provides an updated overview on the pathophysiology of angiogenesis during tumor growth. It also sheds light on the different pro-angiogenic and anti-angiogenic agents that have been developed to date. Finally, it highlights the preclinical evidence for mechanisms of angiogenic resistance and suggests novel therapeutic approaches that might be exploited with the ultimate aim of overcoming resistance and improving clinical outcomes for patients with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–302 of 302
Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies
Rapisarda, A., & Melillo, G. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.03.002 · Cited by 154
Brown, J. L., Cao, Z. A., Pinzon-Ortiz, M. C., Kendrew, J., Reimer, C., Wen, S., Zhou, J. Q., Tabrizi, M. A., Emery, S. C., McDermott, B., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0554 · Cited by 154
Matrix Metalloproteinase Inhibitors as Anticancer Therapeutics
Mannello, F., Tonti, G. A., & Papa, S. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009054064615 · Cited by 150
Viral Vascular Endothelial Growth Factor Plays a Critical Role in Orf Virus Infection
Savory, L. J., Stacker, S. A., Fleming, S. B., NIVEN, B. E., & Mercer, A. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.22.10699-10706.2000 · Cited by 149
Cloning and characterization of a novel human gene related to vascular endothelial growth factor.Preprint
Grimmond, S. M., Lagercrantz, J., Drinkwater, C. C., Silins, G. U., Townson, S. M., Pollock, P. M., Gotley, D. C., Carson, E., Rakar, S., Nordenskjöld, M., et al. (1996) · Genome Research · doi:10.1101/gr.6.2.124 · Cited by 149
Falcón, B. L., Chintharlapalli, S. R., Uhlik, M. T., & Pytowski, B. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.001 · Cited by 149
Vascular endothelial growth factors VEGF-B and VEGF-C
Joukov, V., Kaipainen, A., Jeltsch, M., Pajusola, K., Olofsson, B., Kumar, V., Eriksson, U., & Alitalo, K. K. (1997) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199711)173:2<211::aid-jcp23>3.0.co;2-h · Cited by 148
Castro, B. A., Flanigan, P. M., Jahangiri, A., Hoffman, D. B., Chen, W., Kuang, R., Lay, M. D. D., Yagnik, G., Wagner, J. R., Mascharak, S., et al. (2017) · Oncogene · doi:10.1038/onc.2017.1 · Cited by 148
Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies
Crawford, Y., & Ferrara, N. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.004 · Cited by 144
Mechanisms of pericyte recruitment in tumour angiogenesis: A new role for metalloproteinases
Chantrain, C. F., Henriet, P., Jodele, S., Emonard, H., Féron, O., Courtoy, P. J., DeClerck, Y. A., & Marbaix, É. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.010 · Cited by 144
Fransvea, E., Mazzocca, A., Antonaci, S., & Giannelli, G. (2008) · Hepatology · doi:10.1002/hep.22731 · Cited by 140
Mould, A. W., Tonks, I. D., Cahill, M. M., Pettit, A. R., Thomas, R., Hayward, N. K., & Kay, G. F. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11232 · Cited by 138
Stratman, A. N., Davis, M. J., & Davis, G. E. (2011) · Blood · doi:10.1182/blood-2010-11-316752 · Cited by 137
Chen, Y., Li, X., Eswarakumar, V. P., Seger, R., & Lonai, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203726 · Cited by 135
LaVallee, T. M., Prudovsky, I. A., McMahon, G. A., Hu, X., & Maciag, T. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.7.1647 · Cited by 132
Oblander, S. A., Zhou, Z., Gálvez, B. G., STARCHER, B. C., Shannon, J. M., Durbeej, M., Arroyo, A. G., Tryggvason, K., & Apte, S. (2004) · Developmental Biology · doi:10.1016/j.ydbio.2004.09.033 · Cited by 131
Martin, C., Balasubramanian, R., Dwyer, A. A., Au, M., Sidis, Y., Kaiser, U. B., Seminara, S. B., Pitteloud, N., Zhou, Q., & Crowley, W. F. (2010) · Endocrine Reviews · doi:10.1210/er.2010-0007 · Cited by 128
Hillen, F., Baeten, C. I. M., van de Winkel, A., Creytens, D., van der Schaft, D. W. J., Winnepenninckx, V. J. L., & Griffioen, A. W. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0353-9 · Cited by 126
Angiogenesis Revisited: An Overlooked Role of Endothelial Cell Metabolism in Vessel Sprouting
Vandekeere, S., Dewerchin, M. A., & Carmeliet, P. (2015) · Microcirculation · doi:10.1111/micc.12229 · Cited by 126
Prokineticin 1 Signaling and Gene Regulation in Early Human Pregnancy
Evans, J., Catalano, R. D., Morgan, K., Critchley, H., Millar, R. P., & Jabbour, H. N. (2008) · Endocrinology · doi:10.1210/en.2007-1633 · Cited by 125
Hotchkiss, K. A., Ashton, A. W., Klein, R. S., Lenzi, M. L., Zhu, G. H., & Schwartz, E. L. (2003) · PubMed · Cited by 115
Integration of pro- and anti-angiogenic signals by endothelial cells
Kazerounian, S., & Lawler, J. (2017) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-017-0433-3 · Cited by 113
Ciombor, K. K., Berlin, J. D., & Chan, E. W. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2911 · Cited by 111
Understanding and targeting resistance to anti-angiogenic therapies.
Clarke, J. M., & Hurwitz, H. I. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2013.036 · Cited by 109
The role of CXCR7 on the adhesion, proliferation and angiogenesis of endothelial progenitor cells
Dai, X., Tan, Y., Cai, S., Xiong, X., Wang, L., Ye, Q., Yan, X., Ma, K., & Cai, L. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01301.x · Cited by 109
Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies
Comunanza, V., & Bussolino, F. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00101 · Cited by 109
Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis
Palma, M. D., & Naldini, L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0171 · Cited by 108
Paavonen, K., Horelli‐Kuitunen, N., Chilov, D., Kukk, E., Pennanen, S., Kallioniemi, O., Pajusola, K., Olofsson, B., Eriksson, U., Joukov, V., et al. (1996) · Circulation · doi:10.1161/01.cir.93.6.1079 · Cited by 108
Schmidt, T., & Carmeliet, P. (2010) · Nature · doi:10.1038/465697a · Cited by 108
FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma
Summers, J., Cohen, M. H., Keegan, P., & Pazdur, R. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0250 · Cited by 106
Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs)
Sica, A., Porta, C., Morlacchi, S., Banfi, S., Strauss, L., Rimoldi, M., Totaro, M. G., & Riboldi, E. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0091-6 · Cited by 101
Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models
Park, S. Y., Piao, Y., Jeong, K. J., Dong, J., & de Groot, J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0427 · Cited by 98
Overview of advances in vasculogenic mimicry – a potential target for tumor therapy
Ge, H., & Luo, H. (2018) · Cancer Management and Research · doi:10.2147/cmar.s164675 · Cited by 97
Induction of Bv8 Expression by Granulocyte Colony-stimulating Factor in CD11b+Gr1+ Cells
Qu, X., Zhuang, G., Yu, L., Meng, G., & Ferrara, N. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.326801 · Cited by 96
Burbridge, M. F., Bossard, C. J., Saunier, C., Fejes, I., Bruno, A., Léonce, S., Ferry, G., Violante, G. D., Bouzom, F., Cattan, V., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0075 · Cited by 96
β1 Integrin: Critical Path to Antiangiogenic Therapy Resistance and Beyond
Jahangiri, A., Aghi, M. K., & Carbonell, W. S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1742 · Cited by 93
Botta, C., Barbieri, V., Ciliberto, D., Rossi, A., Rocco, D., Addeo, R., Staropoli, N., Pastina, P., Marvaso, G., Martellucci, I., et al. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.24425 · Cited by 92
Powell, M. A., Sill, M. W., Goodfellow, P. J., Benbrook, D. M., Lankes, H. A., Leslie, K. K., Jeske, Y. W. A., Mannel, R. S., Spillman, M. A., Lee, P. S., et al. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.07.083 · Cited by 91
Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe?
Montero, A. J., Escobar, M., Lopes, G. D. L., Jr., Glück, S., & Vogel, C. L. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0202-z · Cited by 89
Twist1 induces endothelial differentiation of tumour cells through the Jagged1-KLF4 axis
Chen, H., Huang, C.-H., Liu, C., Hung, J., Hsu, C.-C., Teng, S., & Wu, K.-J. (2014) · Nature Communications · doi:10.1038/ncomms5697 · Cited by 88
Chung, A. S., Kowanetz, M., Wu, X., Zhuang, G., Ngu, H., Finkle, D., Kömüves, L. G., Peale, F. V., Jr., & Ferrara, N. (2012) · The Journal of Pathology · doi:10.1002/path.4052 · Cited by 88
Nisancioglu, M. H., Betsholtz, C., & Genové, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4245 · Cited by 87
Grépin, R., Guyot, M., Jacquin, M., Durivault, J., Chamorey, E., Sudaka, A., Serdjebi, C., Lacarelle, B., Scoazec, J., Négrier, S., et al. (2011) · Oncogene · doi:10.1038/onc.2011.360 · Cited by 85
Cross-activating c-Met/β1 integrin complex drives metastasis and invasive resistance in cancer
Jahangiri, A., Nguyen, A. T., Chandra, A., Sidorov, M. K., Yagnik, G., Rick, J. W., Han, S. W., Chen, W., Flanigan, P. M., Schneidman‐Duhovny, D., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1701821114 · Cited by 84
Hainsworth, J. D., Spigel, D. R., Sosman, J. A., Burris, H. A., Farley, C., Cucullu, H., Yost, K., Hart, L. L., Sylvester, L., Waterhouse, D. M., et al. (2007) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2007.n.030 · Cited by 80
Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab
Mitsuhashi, A., Goto, H., Saijo, A., Trung, V. T., Aono, Y., Ogino, H., Kuramoto, T., Tabata, S., Uehara, H., Izumi, K., et al. (2015) · Nature Communications · doi:10.1038/ncomms9792 · Cited by 78
beta1 integrin as a molecular therapeutic target
Cordes, N., & Park, C. C. (2007) · International Journal of Radiation Biology · doi:10.1080/09553000701639694 · Cited by 77
Heterogeneity of tumor endothelial cells
Hida, K., Ohga, N., Akiyama, K., Maishi, N., & Hida, Y. (2013) · Cancer Science · doi:10.1111/cas.12251 · Cited by 76
Anti‐VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
Singh, M., Couto, S. S., Forrest, W. F., Lima, A., Cheng, J. H., Molina, R., Long, J. E., Hamilton, P., McNutt, A., Kasman, I. M., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4053 · Cited by 75
Chiron, M., Bagley, R. G., Pollard, J. R., Mankoo, P. K., Henry, C., Vincent, L., Geslin, C., Baltes, N., & Bergstrom, D. A. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0753 · Cited by 75
Gyanchandani, R., Ortega Alves, M. V., Myers, J. N., & Kim, S. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0358 · Cited by 73
Thomas, M., Kienast, Y., Scheuer, W., Bähner, M., Kaluza, K., Gassner, C., Herting, F., Brinkmann, U., Seeber, S., Kavlie, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054923 · Cited by 73
Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells
Pinto, M. P., Sotomayor, P. C., Carrasco-Aviño, G., Corvalán, A. H., & Owen, G. I. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091489 · Cited by 73
The role of tumor microenvironment in resistance to anti-angiogenic therapy
Ma, S., Pradeep, S., Hu, W., Zhang, D., Coleman, R. L., & Sood, A. K. (2018) · F1000Research · doi:10.12688/f1000research.11771.1 · Cited by 72
Javan, M., Khosrojerdi, A., & Moazzeni, S. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00840 · Cited by 71
Integrins in Tumor Angiogenesis and Lymphangiogenesis
Foubert, P., & Varner, J. A. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-166-6_27 · Cited by 70
Farnebo, F. A., Piehl, F., & Lagercrantz, J. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0562 · Cited by 70
Chiappori, A., Eckhardt, S., Bukowski, R. M., Sullivan, D. M., Ikeda, M., Yano, Y., Yamada‐Sawada, T., Kambayashi, Y., Tanaka, K., Javle, M. M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1586 · Cited by 70
(2000) · doi:10.1002/1096-9896(2000)9999:9999 · Cited by 70
Targeting Hypoxia for Sensitization of Tumors to Radio- and Chemotherapy
Ghattass, K. I., Assah, R., El-Sabban, M. E., et al. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113139990004 · Cited by 70
Contrasting effects of sunitinib within in vivo models of metastasis
Welti, J. C., Powles, T. B., Foo, S., Gourlaouen, M., Preece, N., Foster, J., Frentzas, S., Bird, D., Sharpe, K., van Weverwijk, A., et al. (2012) · Angiogenesis · doi:10.1007/s10456-012-9291-z · Cited by 69
Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors.
Dey, N., De, P. K. R., & Leyland-Jones, B. (2015) · Europe PMC (PubMed Central) · Cited by 68
Hasnis, E., Alishekevitz, D., Gingis‐Velitski, S., Bril, R., Fremder, E., Voloshin, T., Raviv, Z., Karban, A. A., & Shaked, Y. (2014) · Neoplasia · doi:10.1016/j.neo.2014.05.011 · Cited by 67
Yan, X., Cai, S., Xiong, X., Sun, W., Dai, X., Chen, S., Ye, Q., Song, Z., Jiang, Q., & Xu, Z. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24015 · Cited by 67
Norden, A. D., Schiff, D., Ahluwalia, M. S., Lesser, G. J., Nayak, L., Lee, E. Q., Rinne, M. L., Muzikansky, A., Dietrich, J., Purow, B. W., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1631-y · Cited by 65
HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis
Shojaei, F., Simmons, B. H., Lee, J. H., Lappin, P. B., & Christensen, J. G. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.026 · Cited by 63
Qian, C., Tan, M., Yang, J., & Cao, Y. (2016) · 癌症:英文版 · doi:10.1186/s40880-015-0070-2 · Cited by 63
Salnikov, A. V., Heldin, N., Stuhr, L. E. B., Wiig, H., Gerber, H., Reed, R. K., & Rubin, K. (2006) · International Journal of Cancer · doi:10.1002/ijc.22217 · Cited by 61
A rationally designed NRP1-independent superagonist SEMA3A mutant is an effective anticancer agent
Gioelli, N., Maione, F., Camillo, C., Ghitti, M., Valdembri, D., Morello, N., Darche, M., Zentilin, L., Cagnoni, G., Qiu, Y., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aah4807 · Cited by 61
Wang, L., Park, H., Chhim, S., Ding, Y., Jiang, W., Queen, C., & Kim, K. J. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0813 · Cited by 60
Zhang, D., Hedlund, E., Lim, S., Chen, F., Zhang, Y., Sun, B., & Cao, Y. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016220108 · Cited by 59
Albrecht, I., Kopfstein, L., Strittmatter, K., Schomber, T., Falkevall, A., Hagberg, C. E., Lorentz, P., Jeltsch, M., Alitalo, K. K., Eriksson, U., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014109 · Cited by 58
Placental Growth Factor Upregulation Is a Host Response to Antiangiogenic Therapy
Bagley, R. G., Ren, Y., Weber, W. D., Yao, M., Kurtzberg, L. S., Pinckney, J., Bangari, D. S., Nguyen, C., Brondyk, W. H., Kaplan, J. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2687 · Cited by 58
Curtis, V. F., Wang, H., Yang, P., McLendon, R. E., Li, X., Zhou, Q., & Wang, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054916 · Cited by 57
Cold-Induced mRNA Expression of Angiogenic Factors in Rat Brown Adipose Tissue
Asano, A., Kimura, K., & Saito, M. (1999) · Journal of Veterinary Medical Science · doi:10.1292/jvms.61.403 · Cited by 54
Hepatic expression of ANG2 RNA in metastatic colorectal cancer
Ogawa, M., Yamamoto, H., Nagano, H., Miyake, Y., Sugita, Y., Hata, T., Kim, B.-N., Ngan, C. Y., Damdinsuren, B., Ikenaga, M., et al. (2004) · Hepatology · doi:10.1002/hep.20048 · Cited by 53
Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?
Coelho, A., Gomes, M. P., Catarino, R., Rolfo, C. D., Lopes, A. M., Medeiros, R., & Araújo, A. (2016) · Oncotarget · doi:10.18632/oncotarget.7794 · Cited by 51
Class 3 semaphorins: physiological vascular normalizing agents for anti‐cancer therapy
Serini, G., Bussolino, F., Maione, F., & Giraudo, E. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12017 · Cited by 48
Tumor-Associated Fibroblasts as “Trojan Horse” Mediators of Resistance to Anti-VEGF Therapy
Francia, G., Emmenegger, U., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.011 · Cited by 47
Clinical Significance of VEGF-A, -C and -D Expression in Esophageal Malignancies
Kleespies, A., Bruns, C. J., & Jauch, K. (2005) · Oncology Research and Treatment · doi:10.1159/000085198 · Cited by 47
Lassen, U., Chinot, O. L., McBain, C. A., Mau‐Sørensen, M., Larsen, V. A., Barrié, M., Roth, P., Krieter, O., Wang, K., Habben, K., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov019 · Cited by 45
Antiangiogenic Agents in Cancer Therapy
Lenz, H. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-184-0 · Cited by 45
Azab, A. K., Şahin, İ., Azab, F., Moschetta, M., Mishima, Y., Burwick, N. R., Zimmermann, J., Romagnoli, B., Patel, K., Chevalier, É., et al. (2014) · Blood · doi:10.1182/blood-2014-02-558742 · Cited by 44
Wakelee, H. A., Zvirbule, Z., de Braud, F., Kingsley, C. D., Mekhail, T. M., Lowe, T., Schütte, W., Léna, H., Lawler, W. E., Braiteh, F., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.09.013 · Cited by 43
Yehia, L., Boulos, F. I., Jabbour, M. N., Mahfoud, Z. R., Fakhruddin, N., & El-Sabban, M. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129356 · Cited by 42
Vascular endothelial growth factor receptor 3 in hypoxia‐induced vascular development
Nilsson, I., Rolny, C., Wu, Y. L., Pytowski, B., Hicklin, D., Alitalo, K. K., Claesson, L., & M, S. W. ̈. (2004) · The FASEB Journal · doi:10.1096/fj.03-1276com · Cited by 42
Zhou, Y., Tu, C., Zhao, Y., Liu, H., & Zhang, S. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.073 · Cited by 39
Chen, X., Chen, Z.-Q., Zhu, S.-L., Liu, T.-W., Wen, Y., Su, Y.-S., Xi, X.-J., Hu, Y., Lian, L., & Liu, F. (2017) · BMC Cancer · doi:10.1186/s12885-017-3215-7 · Cited by 39
Boere, I. A., Hamberg, P., & Sleijfer, S. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01369.x · Cited by 38
Montmayeur, J., Valius, M., Vandenheede, J. R., & Kazlauskas, A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.51.32670 · Cited by 38
Dirican, A., Varol, U., Küçükzeybek, Y., Alacacıoğlu, A., Erten, Ç., Somali, I., Can, A., Demir, L., Bayoğlu, İ. V., Akyol, M., et al. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.12.4781 · Cited by 30
Çetin, B., Ma, K., Berk, V., Ozturk, S. C., Beneklı, M., Işıkdoğan, A., Özkan, M., Çoşkun, U., & Buyukberber, S. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.3.1059 · Cited by 30
Liu, B. Y., Soloviev, I., Chang, P., Lee, J., Huang, X.-D., Zhong, C., Ferrara, N., Polakis, P. G., & Sakanaka, C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008611 · Cited by 28
Semrad, T. J., Kim, E. J.-H., Tanaka, M. S., Sands, J. M., Roberts, C., Burich, R. A., Li, Y., Gandara, D. R., Lara, P. N., & Mack, P. C. (2016) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2016.12.002 · Cited by 28
Czabanka, M., Brünner, J., Parmaksiz, G., Broggini, T., Topalovic, M., Bayerl, S., Auf, G., Kremenetskaia, I., Nieminen-Kelhä, M., Jabouille, A., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.019 · Cited by 26
Lee, C., Lee, M. E., Lee, W. S., Kim, J., Park, K.-H., Kim, T. S., Lee, K. Y., Ahn, J. B., Chung, H. C., & Rha, S. Y. (2015) · Europe PMC (PubMed Central) · Cited by 25
VEGF and Pleiotrophin Modulate the Immune Profile of Breast Cancer
Lynn, K. D., Roland, C. L., & Brekken, R. A. (2010) · Cancers · doi:10.3390/cancers2020970 · Cited by 25
Chemotherapy Counteracts Metastatic Dissemination Induced by Antiangiogenic Treatment in Mice
Rovida, A., Castiglioni, V., Decio, A., Scarlato, V., Scanziani, E., Giavazzi, R., & Cesca, M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0244 · Cited by 24
Kumar, S., Mokhtari, R. B., Oliveira, I. D., Islam, S. S., de Toledo, S. R. C., Yeger, H., & Baruchel, S. (2013) · Translational Oncology · doi:10.1593/tlo.13286 · Cited by 22
Clarke, J. M., Blobe, G. C., Strickler, J. H., Uronis, H. E., Zafar, S. Y., Morse, M., Dropkin, E., Howard, L., O’Neill, M., Rushing, C. N., et al. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03916-0 · Cited by 18
Resistance to Inhibitors of Angiogenesis
Dahan, N., Magidey, K., & Shaked, Y. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_9 · Cited by 5
Mechanisms of Reversible Sorafenib Resistance in Hepatocellular Carcinoma
Kuczynski, E. A. (2016) · TSpace (University of Toronto) · Cited by 2
Cited by
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Ganesh, K., & Massagué, J. (2021) · Nature Medicine · doi:10.1038/s41591-020-01195-4 · Cited by 1,051
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Pathological angiogenesis: mechanisms and therapeutic strategies
Dudley, A. C., & Griffioen, A. W. (2023) · Angiogenesis · doi:10.1007/s10456-023-09876-7 · Cited by 495
Metadata
- Authors
- Haibe, Y., Kreidieh, M., El Hajj, H., Khalifeh, I., Mukherji, D., Temraz, S., & Shamseddine, A.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-02-27
- Volume
- 10
- Pages
- 221-221
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3007442940
- Cited by
- 396
- References
- 302
- FWCI
- 15.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.